Tags : Sangamo

Top 20

Top 20 Life Sciences Deals of 2020 by Total Deal

Life sciences companies are gearing up to enter new markets as they look to secure their positions after a spate of M&A, licensing, and research partnerships in 2020 Artios partnered with Merck with an option to license up to 8 oncology programs proving to be the highest valued deal of 2020 with a total deal […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

 1.  Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia  Published: Jun 19, 2020 | Tags: Ultragenyx, Kyowa Kirin, Crysvita, burosumab, Receives, US, FDA, Approval, Treatment, Tumor-Induced Osteomalacia 2.  Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A Published: Jun 18, 2020 […]Read More


Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in

Shots: Pfizer and Sangamo report follow-up data from the P-I/II Alta study assessing giroctocogene fitelparvovec (SB-525, or PF-07055480) in 11 patients aged 18-47yrs. with severe hemophilia A 5 patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels, with a median of 64.2% via chromogenic assay as […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (April 20 -24, 2020)

1. Sanofi Receives the US FDA’s Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine Published: Apr 23, 2020 | Tags: Sanofi, Receives, US, FDA, Approval, MenQuadfi, Meningococcal, MenACWY, Conjugate Vaccine 2.  Takeda to Divest Select OTC and Non-Core Assets in Europe to Orifarm for $670M Published: Apr 24, 2020 | Tags: Takeda, Divest, Select OTC and […]Read More


Sangamo Signs an Exclusive License Agreement with Mogrify for iPSC

Shots: Shots: Mogrify to receive upfront, development, regulatory and commercial milestones and will be responsible for the discovery & optimization of the cell conversion technology from iPSCs or ESCs to regulatory T cells Sangamo to get exclusive rights to use Mogrify’s technology to develop Tregs from iPSCs/ESCs. The company anticipates utilizing its ZFP technology & […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (February 24-28, 2020)

1. Companion Medical’s InPen Diabetes Management System Receives the US FDA’s Approval for Fixed Dosing and Meal Estimation Published: Feb 28, 2020 | Tags: Companion Medical, InPen Diabetes Management System, Receives, US, FDA, Approval, Fixed Dosing, Meal Estimation 2.  Takeda’s Vedolizumab SC Receives CHMP’s Positive Opinion as a Maintenance Therapy for Moderately to Severely Active […]Read More


Sangamo Highlights its Genomic Medicine Pipeline at R&D Day 2019

Shots: Sangamo provides an update on its pre/ clinical pipeline and emphasizes on its global capabilities across clinical science, operations, product development and manufacturing at its R&D day The company highlights the completion of IND transfer to Pfizer for its gene therapy candidate, SB-525 with the expected onset of its P-III study in 2020 by […]Read More